Triple negative breast cancer patients presenting with low serum vitamin D levels: a case series

Abstract Background Several studies have recently reported that the relationships between serum vitamin D and the prognosis or the pathological response to neoadjuvant chemotherapy (NAC) in breast cancer. However, there are no data regarding the clinical impacts of the vitamin D in Japanese breast cancer patients so far. Patients and methods In the present study, a total of 250 patients with clinical Stage I–III primary breast cancer who were treated with NAC and subsequently underwent definitive surgery were included. Serum 25-hydroxvitamin D (25(OH)D) levels were evaluated using blood samples obtained before NAC. Results The serum 25(OH)D was positively associated with age, and the serum 25(OH)D was significantly higher in postmenopausal women than that in pre/peri-menopausal women. Serum 25(OH)D level was not associated with the achievement of pathological complete response (pCR) in this cohort. The low 25(OH)D levels were significantly associated with shorter time to distant recurrence (TTDR). According to the univariate analysis, high clinical stage before NAC (cStage III) and low serum 25(OH)D level were significantly associated with the shorter TTDR, and pCR was significantly associated with the longer TTDR. According to a multivariate analysis, low serum 25(OH)D level were independent poor prognostic factors for TTDR. Conclusions The low 25(OH)D levels were significantly associated with poorer prognosis in Japanese women with operable breast cancer patients treated with NAC.

Download Full-text

Abstract B09: Serum vitamin D levels in breast cancer patients to assess its risk prediction to improve health

10.1158/1538-7755.carisk16-b09 ◽

2017 ◽

Author(s):

Vinit Mehrotra ◽

Ashutosh Sharma

Keyword(s):

Breast Cancer ◽

Vitamin D ◽

Cancer Patients ◽

Risk Prediction ◽

Serum Vitamin ◽

Breast Cancer Patients ◽

Serum Vitamin D ◽

Vitamin D Levels ◽

Improve Health

Download Full-text

The association between fat mass and obesity‐associated ( FTO ) genotype and serum vitamin D level in breast cancer patients

Journal of Cellular and Molecular Medicine ◽

10.1111/jcmm.16908 ◽

2021 ◽

Vol 25 (20) ◽

pp. 9627-9633

Author(s):

Maryam Gholamalizadeh ◽

Zohreh Mokhtari ◽

Saeid Doaei ◽

Vahideh Jalili ◽

Sayed Hossein Davoodi ◽

...

Keyword(s):

Breast Cancer ◽

Vitamin D ◽

Cancer Patients ◽

Fat Mass ◽

Serum Vitamin ◽

Breast Cancer Patients ◽

Serum Vitamin D

Download Full-text

Circulating Vitamin D and Overall Survival in Breast Cancer Patients: A Dose-Response Meta-Analysis of Cohort Studies

Integrative Cancer Therapies ◽

10.1177/1534735417712007 ◽

2017 ◽

Vol 17 (2) ◽

pp. 217-225 ◽

Cited By ~ 20

Author(s):

Kejia Hu ◽

David Frederick Callen ◽

Jiayuan Li ◽

Hong Zheng

Keyword(s):

Breast Cancer ◽

Vitamin D ◽

Overall Survival ◽

Cancer Patients ◽

Dose Response ◽

Fixed Effects ◽

Meta Analysis ◽

Breast Cancer Patients ◽

Fixed Effects Model ◽

Vitamin D Levels

Studies have shown that vitamin D could have a role in breast cancer survival; however, the evidence of the relationship between patients’ vitamin D levels and their survival has been inconsistent. This meta-analysis explores possible dose-response relationships between vitamin D levels and overall survival by allowing for differences in vitamin D levels among populations of the various studies. Studies relating vitamin D (25-OH-D [25-hydroxyvitamin D]) levels in breast cancer patients with their survival were identified by searching PubMed and Embase. A pooled HR (hazard ratio) comparing the highest with the lowest category of circulating 25-OH-D levels were synthesized using the Mantel-Haenszel method under a fixed-effects model. A two-stage fixed-effects dose-response model including both linear (a log-linear dose-response regression) and nonlinear (a restricted cubic spline regression) models were used to further explore possible dose-response relationships. Six studies with a total number of 5984 patients were identified. A pooled HR comparing the highest with the lowest category of circulating 25-OH-D levels under a fixed-effects model was 0.67 (95% confidence interval = 0.56-0.79, P < .001). Utilizing a dose-response meta-analysis, the pooled HR for overall survival in breast cancer patients was 0.994 (per 1 nmol/L), Pfor linear trend < .001. At or above a 23.3 nmol/L threshold, for a 10 nmol/L, 20 nmol/L, or 25 nmol/L increment in circulating 25-OH-D levels, the risk of breast cancer overall mortality decreased by 6%, 12%, and 14%, respectively. There was no significant nonlinearity in the relationship between overall survival and circulating 25-OH-D levels. Our findings suggest that there is a highly significant linear dose-response relationship between circulating 25-OH-D levels and overall survival in patients with breast cancer. However, better designed prospective cohort studies and clinical trials are needed to further confirm these findings.

Download Full-text

Low Serum Vitamin D is Independently Associated with Acute Ischemic Stroke

Medicine Today ◽

10.3329/medtoday.v30i1.35564 ◽

2018 ◽

Vol 30 (1) ◽

pp. 34-37

Author(s):

Md Mahabubul Islam Majumder ◽

Md Nazmul Hasan Chowdhury ◽

Ashiqur Rahman Khan ◽

Tarek Ahmed ◽

Saleh Ahmed

Keyword(s):

Vitamin D ◽

Ischemic Stroke ◽

Acute Stroke ◽

Acute Ischemic Stroke ◽

Serum Vitamin ◽

Multivariate Logistic Regression Analysis ◽

Vitamin D Status ◽

Serum Vitamin D ◽

Vitamin D Levels ◽

Low Serum

Low serum vitamin D levels have been associated with various vascular diseases. Very little is known its association with acute stroke in Bangladeshi population. We therefore sought to assess whether low serum 25- hydroxyvitamin D, a marker of vitamin D status is associated with acute stroke. We performed a prospective study in Comilla Medical Collage, Comilla, from November 2016 to November 2017. All the patients diagnosed as acute ischemic stroke on the basis of CT scan or MRI of brain. Patients were eligible for inclusion if they were admitted with onset of symptoms within 24 hours. Estimation of 25(OH)D level was done at presentation. The patients were stratified by vitamin D status, >30 as vitamin D sufficient, vitamin D 20-20.9 as insufficient and finally vitamin D<20 as deficient. Multivariate logistic regression analysis revealed that out of the desired 7 variables, smoking, hypertension and low serum vitamin D were found independent predictors for acute stroke with ORs being 1.44, 4.23 and 2.39 respectively. Vitamin D deficiency represents an important risk factor for acute stroke and it might play a causal role in the development adverse events associated with stroke.Medicine Today 2018 Vol.30(1): 34-37

Download Full-text

A170 VITAMIN D IN IBD PATIENTS – A RETROSPECTIVE REVIEW

Journal of the Canadian Association of Gastroenterology ◽

10.1093/jcag/gwz047.169 ◽

2020 ◽

Vol 3 (Supplement_1) ◽

pp. 35-36

Author(s):

R A MacMillan ◽

T Ponich

Keyword(s):

Vitamin D ◽

Bone Density ◽

Disease Severity ◽

Regression Coefficient ◽

Serum Vitamin ◽

Vitamin D Supplementation ◽

Serum Vitamin D ◽

Mayo Score ◽

Vitamin D Levels ◽

Low Serum

Abstract Background Vitamin D is a critical factor in bone remodelling, calcium absorption and may promote anti-inflammatory cytokines in the gut. Inflammatory bowel disease (IBD) is associated with a reduction in serum Vitamin D levels and a chronic inflammatory state, both of which are strong risk factors for bone density loss affecting IBD patients. Despite European and North American IBD maintenance guidelines for Vitamin D monitoring and bone density scans, there are limited North American investigations into factors influencing serum Vitamin D levels in the IBD patient population specifically. Aims We investigated whether patient demographics, disease severity indexes and/or inflammatory markers were linked to low serum Vitamin D levels in our IBD patients. We also established the extent of Vitamin D serum deficiencies and supplementation rates in our IBD patients. Methods A retrospective chart review of a single clinician’s practice at London Health Science Centre, Victoria Hospital, over the past 20 months, was performed to: 1) assess the frequency of low serum 25-OH Vitamin D (25-OH D) in the IBD patient population and 2) determine whether patient disease severity was linked to lower 25-OH D levels. A multivariate regression analysis was performed assessing Crohn’s Disease (CD) or Ulcerative Colitis (UC) patient factors: age, sex, disease duration, seasonality, current pharmacologic treatments, past surgeries, CD Activity Index, UC Mayo score, C-reactive protein, and fecal calprotectin (Fcal) level. Results 175 IBD patients had at least one 25-OH D measurement with 71 patients actively on Vitamin D therapy. Of UC and CD patients who were not on Vitamin D therapy, 63% (17/27) and 79% (61/77) were 25-OH D deficient, respectively. 25-OH D levels in the CD population was associated with Vitamin D supplementation (regression coefficient [RC] 23.99, 95% confidence interval [CI] 14.54 to 33.45), summer season ([RC] 9.90, [CI] 0.56 to 19.24), and past bowel resection ([RC] -10.61, [CI] -20.48 to -0.76). 25-OH D levels in the UC population was associated with Vitamin D supplementation (regression coefficient [RC] 47.23, 95% confidence interval [CI] 27.62 to 66.83), and Mayo severity scores ([RC] -23.01, [CI] -41.82 to -4.20). Fcal (78 patients) was inversely associated with 25-OH D levels but the trend was not significant. Conclusions Overall, 25-OH D levels were lower in both the UC and CD patient populations relative to the already deficient Canadian population. However, IBD patients are responsive to Vitamin D supplementation. Tools with more objective evidence of disease severity such as UC Mayo score and fcal should be prioritized for identifying the IBD population requiring supplementation. Funding Agencies None

Download Full-text

Serum Vitamin D Levels Affect Pathologic Complete Response in Patients Undergoing Neoadjuvant Systemic Therapy for Operable Breast Cancer

Clinical Breast Cancer ◽

10.1016/j.clbc.2017.12.001 ◽

2018 ◽

Vol 18 (2) ◽

pp. 144-149 ◽

Cited By ~ 5

Author(s):

Akiko Chiba ◽

Rachna Raman ◽

Alexandra Thomas ◽

Pierre-Jean Lamy ◽

Marie Viala ◽

...

Keyword(s):

Breast Cancer ◽

Vitamin D ◽

Systemic Therapy ◽

Pathologic Complete Response ◽

Serum Vitamin ◽

Complete Response ◽

Operable Breast Cancer ◽

Serum Vitamin D ◽

Neoadjuvant Systemic Therapy ◽

Vitamin D Levels

Download Full-text

Decreased Neuromuscular Function in Crohn’s Disease Patients Is Not Associated with Low Serum Vitamin D Levels

Digestive Diseases and Sciences ◽

10.1007/s10620-012-2372-4 ◽

2012 ◽

Vol 58 (2) ◽

pp. 526-533 ◽

Cited By ~ 7

Author(s):

Amanda J. Salacinski ◽

Miguel D. Regueiro ◽

Craig E. Broeder ◽

Jean L. McCrory

Keyword(s):

Vitamin D ◽

Crohn’S Disease ◽

Crohn's Disease ◽

Serum Vitamin ◽

Neuromuscular Function ◽

Serum Vitamin D ◽

Vitamin D Levels ◽

Low Serum

Download Full-text

Variations in serum vitamin D status during cancer chemotherapy.

Journal of Clinical Oncology ◽

10.1200/jco.2012.30.15_suppl.e19550 ◽

2012 ◽

Vol 30 (15_suppl) ◽

pp. e19550-e19550

Author(s):

Bogda Koczwara ◽

Richard John Woodman ◽

Laisa Vicki Teleni ◽

Michael Kimlin ◽

Euan Thomas Walpole ◽

...

Keyword(s):

Vitamin D ◽

Demographic Data ◽

Serum Vitamin ◽

Sun Exposure ◽

Unknown Primary ◽

Curative Intent ◽

Serum Vitamin D ◽

Vitamin D Levels ◽

The Impact ◽

Low Serum

e19550 Background: Low serum vitamin D in cancer patients has been associated with inferior cancer outcomes and bone loss. The impact of chemotherapy on vitamin D levels is not known. We examined serum vitamin D levels during chemotherapy to identify magnitude and predictors of change. Methods: A prospective study of chemotherapy naïve patients commencing chemotherapy in two different sun exposure areas. Vitamin D (25(OH)D) deficiency was defined as ≤25 nmol/L and insufficiency 26-50 nmol/L. Demographic data, nutrition, sun exposure, season and biochemical parameters were collected at baseline 6 weeks (6W) and 12 weeks (12W) since commencement of treatment. The effects were assessed using a multivariate multilevel linear regression model that also included age, gender and BMI. Results: 82 Caucasian and 3 indigenous patients were enrolled. Median age was 57 (21-85) years. Forty-nine (58%) were female; 54 (65%) were treated with curative intent. Tumours included 29 (34%) breast,12 (14%) colorectal, 9 (11%) lymphomas, 7 (8%) leukemias, 7 (8%) lung, 5 (6%) ovarian, 3 (4%) testis, 3 (4%) unknown primary and 10 (11%) others. Median weight was 75 kg (50-151) and median BMI was 26.9 kg/m2 (17.7- 44.5). Seventy-six (89%) and 55 (65%) patients were receiving chemotherapy treatment at 6W and 12W respectively. Mean (±SD) serum 25(OH)D at baseline was 49.2±22.3 nmol/L. Ten (12%) patients were vitamin D deficient at baseline and a further 33 (41%) had insufficient levels. Mean serum 25(OH)D status was higher in higher sun exposure locations (61.9±22.1 nmol/L vs 42.2±19.2 nmol/L, p<0.001), varied according to season (spring=46.9±20.3 nmol/L, summer=50.8±18.2 nmol/L, fall=76.4±25.2 nmol/L, winter=36.5±15.7 nmol/L, p<0.001) and changed with treatment period (baseline=49.2±22.3 nmol/L, 6W=40.9±19.0 nmol/L, 12W=45.9±19.7 nmol/L, p=0.002). There was no association between 25(OH)D status and age, gender, BMI or nutritional status. Conclusions: Chemotherapy is associated with a fall in serum 25(OH)D. Further research is needed to determine the underlying mechanism, the impact of low serum 25(OH)D on patient outcomes and the potential role for screening and vitamin D supplementation in this group.

Download Full-text